The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain

Opioids No Better Than NSAIDs for Chronic Back or Arthritis Pain

March 7, 2018 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests.

You Might Also Like
  • Nonopioid Medication May Be as Effective as Opioids for Chronic Pain
  • U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids
  • Lilly Says New Type of Pain Drug Could Reduce Need for Opioids

And opioids are no better than these other drugs at reducing how much pain interferes with daily activities, such as walking, working, sleeping or enjoying life, researchers report in JAMA, online March 6.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We already knew opioids were more dangerous than other treatment options, because they put people at risk for accidental death and addiction,” says lead study author Dr. Erin Krebs of the Minneapolis VA Health Care System and the University of Minnesota.

“This study shows that extra risk doesn’t come with any extra benefit,” Krebs says by email.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. deaths from opioids, including heroin and such prescription drugs as oxycodone, hydrocodone and methadone, have more than quadrupled since 1999, according to the Centers for Disease Control and Prevention (CDC) in Atlanta. Today, more than six in 10 drug overdose deaths involve opioids.

Amid this worsening opioid crisis, the CDC has urged physicians to use opioids only as a last resort. Instead, doctors should talk to patients about the potential for exercise or physical therapy to help ease symptoms and prescribe other, less addictive drugs for pain, including acetaminophen (Tylenol) and such NSAIDS as aspirin, ibuprofen (Advil, Motrin) and naproxen (Aleve).

NSAIDs carry their own risks, especially at high doses, including the potential for internal bleeding, kidney damage and heart attacks. But they aren’t addictive.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For the current study, researchers randomly assigned 240 patients seeking pain treatment at VA primary care clinics to receive either opioids or alternative medicines like acetaminophen or ibuprofen for one year.

Participants were 58 years old on average and most were men. Back pain was their most common complaint, affecting 156 patients, or 65%, and the rest had either hip or knee osteoarthritis pain.

People in the opioid group started therapy with fast-acting morphine, a combination of hydrocodone and acetaminophen, or immediate release oxycodone. If that wasn’t successful, patients next got long-acting morphine or oxycodone, and then doctors tried fentanyl patches.

In the non-opioid group, patients first got acetaminophen and NSAIDs. If those options didn’t help enough, doctors tried options, such as the nerve pain drug gabapentin (Neurontin) and topical painkillers like lidocaine, followed by the nerve pain drug pregabalin (Lyrica) and tramadol, an opiate painkiller.

Researchers asked participants to rate how much pain interfered with their lives at the start of the study, and again 12 months later.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: Chronic pain, hip, hip pain, Knee Osteoarthritis (OA), Nonsteroidal anti-inflammatory drugs (NSAIDs), NSAIDs, Opioids, osteoarthritis (OA), Pain, Pain Management

You Might Also Like:
  • Nonopioid Medication May Be as Effective as Opioids for Chronic Pain
  • U.S. Agency Issues New Guidelines to Limit Chronic Use of Opioids
  • Lilly Says New Type of Pain Drug Could Reduce Need for Opioids
  • Medical Cannabis Helps Chronic Pain Patients Cut Opioid Use

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.